Is Theravance Biopharma, Inc. overvalued or undervalued?

As of 17 October 2025, the valuation grade for Theravance Biopharma, Inc. has moved from attractive to expensive, indicating a shift towards overvaluation. The company is currently considered overvalued based on its financial metrics, including a Price to Book Value of 3.39, an EV to Sales ratio of 7.25, and a negative EV to EBITDA of -11.24.
In comparison to peers, Evolus, Inc. has a P/E ratio of -8.24 and an EV to EBITDA of -15.57, while Aclaris Therapeutics, Inc. shows a P/E of -4.88 and an EV to EBITDA of -2.19, highlighting that Theravance's metrics are significantly higher than those of its competitors. Despite strong recent returns, such as a 51.54% year-to-date return compared to the S&P 500's 13.30%, the overall valuation suggests that Theravance Biopharma is not a compelling investment at its current price level.